<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23166" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Familial Hypercholesterolemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaezi</surname>
            <given-names>Zahra</given-names>
          </name>
          <aff>Zahedan University of Medical Sciences, Iran</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amini</surname>
            <given-names>Afshin</given-names>
          </name>
          <aff>St. Luke's Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zahra Vaezi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Afshin Amini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23166.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Familial hypercholesterolemia is a group of inherited genetic defects that lead to the severe elevation of serum cholesterol concentrations. Clinically familial hypercholesterolemia is diagnosed by a high serum level of low-density lipoprotein (LDL) cholesterol and genetically is characterized into two subgroups: (1) autosomal dominant (AD), (2) codominant transmission with 90% or higher penetrance. This activity reviews the evaluation and management of familial hypercholesterolemia and highlights the interprofessional team's role in evaluating and treating patients with this disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of familial hypercholesterolemia.</p></list-item><list-item><p>Outline the appropriate evaluation of familial hypercholesterolemia.</p></list-item><list-item><p>Review the treatment options available for familial hypercholesterolemia.</p></list-item><list-item><p>Describe the interprofessional team strategies for improving care coordination and communication to optimize the treatment of familial hypercholesterolemia and improve its outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23166&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23166">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23166.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Familial hypercholesterolemia (FH) is a group of inherited genetic defects that lead to the severe elevation of serum cholesterol concentrations. Clinically familial hypercholesterolemia is diagnosed by a high serum level of low-density lipoprotein (LDL) cholesterol and genetically is characterized into two subgroups: (1) autosomal dominant (AD), (2) codominant transmission with 90% or higher penetrance.<xref ref-type="bibr" rid="article-23166.r1">[1]</xref> A dominant trait transmission is the most common type of familial hypercholesterolemia. In the Fredrickson classification, patients with familial hypercholesterolemia have been seen in type 2a, 2b, and 3 hyperlipidemias; however, type 2a is the most common familial hypercholesterolemia type.<xref ref-type="bibr" rid="article-23166.r2">[2]</xref>&#x000a0;Elevation of serum LDL cholesterol in patients with familial hypercholesterolemia leads to an increase in the risk of atherosclerotic disease and, subsequently, premature death.<xref ref-type="bibr" rid="article-23166.r3">[3]</xref>&#x000a0;Early detection of familial hypercholesterolemia and aggressive management to lower the LDL cholesterol level helps in preventing or slowing the progression of coronary atherosclerosis. First-degree relatives of a patient with FH should be screened, so that other gene carriers can be identified and treated.<xref ref-type="bibr" rid="article-23166.r4">[4]</xref></p>
      </sec>
      <sec id="article-23166.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The three main known genetic mutations in familial hypercholesterolemia are classified as defects in the LDL receptor (most common), apolipoprotein B &#x000a0;(ApoB), or proprotein convertase subtilisin/Kexin type 9 (PCSK9). Each of these three mutations leads to impairment of LDL receptors and a reduction in uptake of LDL cholesterol and subsequently causes high LDL cholesterol concentration.<xref ref-type="bibr" rid="article-23166.r5">[5]</xref><xref ref-type="bibr" rid="article-23166.r6">[6]</xref>&#x000a0;Patients can have a homozygous or a heterozygous defect, which will determine the severity of the disease and the age of onset of cardiovascular (CV )disease manifestations. Children who carry both defect genes from two heterozygote parents almost do not have LDLR to uptake LDL and subsequently present with extremely high LDL cholesterol levels and early-onset CV disease.<xref ref-type="bibr" rid="article-23166.r7">[7]</xref>&#x000a0;Over 1600 gene mutations in LDLR are detected in 85 to 90% of patients with familial hypercholesterolemia. APOB mutations accounting for about 10% of patients with familial hypercholesterolemia, and from this amount, the Arg3500Gln gene mutation is the most common cause. PCSK9 gene mutation causes less than 5% of patients with familial hypercholesterolemia. Moreover, only severe mutations in PCSK9 can lead to familial hypercholesterolemia.<xref ref-type="bibr" rid="article-23166.r8">[8]</xref>&#x000a0;However, a less common mutation in signal-transducing adaptor family member 1 (<italic toggle="yes">STAP1</italic>) was also reported to cause familial hypercholesterolemia.<xref ref-type="bibr" rid="article-23166.r9">[9]</xref></p>
      </sec>
      <sec id="article-23166.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The study by De Ferranti et al. has estimated that familial hypercholesterolemia occurs in about 1 in 250 individuals older than 20-year-old in the United States. The most common age prevalence was from 60 to 69 years old, while the least common age prevalence was 20 to 29 years old. Also, familial hypercholesterolemia had a similar prevalence between men and women but was more common in the obese or black race.<xref ref-type="bibr" rid="article-23166.r10">[10]</xref>&#x000a0;Other studies have also estimated the prevalence of familial hypercholesterolemia in other countries. Results revealed 1 in 217 individuals in Denmark, 1 in 150 among French Canadians in Quebec, and 1 in 70 among Afrikaners in South Africa.<xref ref-type="bibr" rid="article-23166.r11">[11]</xref><xref ref-type="bibr" rid="article-23166.r12">[12]</xref><xref ref-type="bibr" rid="article-23166.r13">[13]</xref>&#x000a0;Heterozygous familial hypercholesterolemia is estimated at 1 in 300 to 500 people, from which it can be concluded that approximately 10 million people have familial hypercholesterolemia worldwide.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
        <p>
<bold>Race</bold>
</p>
        <p>Finnish, Afrikaner, Lebanese, Ashkenazi Jewish, or French Canadian origins have a higher prevalence of FH.</p>
        <p>
<bold>Sex</bold>
</p>
        <p>The inheritance pattern is the same for males and females because the gene for FH is on chromosome 19.</p>
        <p>
<bold>Age</bold>
</p>
        <p>A&#x000a0;defective LDL receptor&#x000a0;is present at birth, but the longer patients live with extremely elevated LDLc levels, the higher their risk of CAD.</p>
      </sec>
      <sec id="article-23166.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Low-density lipoprotein (LDL) transports the majority of plasma cholesterol and binding to the low-density lipoprotein receptor (LDLR) cell membrane through&#x000a0;two ligands on LDL, apolipoprotein B-100 (apoB-100) and apoE. The complex of LDL and LDLR enters the cells, then LDL is released, and LDLR recycles to the cell membrane.<xref ref-type="bibr" rid="article-23166.r15">[15]</xref></p>
        <p>The liver secretes the proprotein PCSK9 that extracellularly binds to LDLR and inhibits the recycling of LDLR to the cell membrane. Therefore, PCSK9 leads to a decrease in LDLR and increases serum LDL.<xref ref-type="bibr" rid="article-23166.r8">[8]</xref>&#x000a0;The end-result in all three main gene mutations is the binding dysfunction of LDL receptors to the LDL cholesterol, thereby decreasing the uptake and destruction of LDL cholesterol in the liver and the resultant rise in serum LDL levels.<xref ref-type="bibr" rid="article-23166.r5">[5]</xref>&#x000a0;Clinically, it can not determine the causal gene mutation in familial hypercholesterolemia.<xref ref-type="bibr" rid="article-23166.r16">[16]</xref></p>
        <p>
<bold>LDL Receptor Genetic Defects</bold>
</p>
        <p>The impairment of LDLR results in decreased LDL clearance from the plasma and an elevation of low-density lipoprotein cholesterol&#x000a0;(LDL-C ), which causes increased uptake of oxidase LDL or other modifications by macrophages and resulting in foam cell formation.<xref ref-type="bibr" rid="article-23166.r17">[17]</xref>&#x000a0;Gene mutation of LDLR can be categorized into 5 classes based on protein mutation.</p>
        <list list-type="bullet">
          <list-item>
            <p>Class 1 &#x02013; Null, due to defect in the synthesis of LDLR</p>
          </list-item>
          <list-item>
            <p>Class 2 &#x02013; Transport defective, in which impairment in the transport of LDLR from the endoplasmic reticulum to Golgi in the cells.</p>
          </list-item>
          <list-item>
            <p>Class 3 &#x02013; Binding defect, in which ability dysfunction of LDLR to bind with LDL.</p>
          </list-item>
          <list-item>
            <p>Class 4 &#x02013; Internalization defect, in which the LDL receptors do not cluster in the clathrin-coated pits, so minimizing LDL internalization by the hepatocyte.<xref ref-type="bibr" rid="article-23166.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Class 5 - Recycling defect, in which LDLR is not recycling to the cell membrane.<xref ref-type="bibr" rid="article-23166.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Familial Defective Apolipoprotein B-100</bold>
</p>
        <p>This disorder is related to a defect in the apoB-100 ligand on the LDL. Therefore, it reduces the LDL clearance from plasma and subsequently causes a high level of serum LDL.<xref ref-type="bibr" rid="article-23166.r20">[20]</xref></p>
        <p>
<bold>Mutations in the PCSK9 Gene</bold>
</p>
        <p>Mutations that cause increased activity of PCSK9 lead to increased degradation of the LDL receptor and subsequently elevation of plasma LDL. However, mutations that inactivate PCSK9 cause lower plasma LDL levels and reduce coronary heart disease (CHD).<xref ref-type="bibr" rid="article-23166.r21">[21]</xref></p>
      </sec>
      <sec id="article-23166.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Homozygous Familial Hypercholesterolemia</bold>
</p>
        <p>These patients have symptoms of ischemic heart disease, peripheral vascular disease, cerebrovascular disease, or aortic stenosis. Patients may have tendonitis or arthralgia and a history of unusual skin lesions. Survival beyond 30 years of age is difficult unless treated with unusual methods.</p>
        <p>
<bold>Heterozygous Familial Hypercholesterolemia</bold>
</p>
        <p>These patients have severe hypercholesterolemia since childhood. Symptoms of ischemic heart disease are common, especially if other cardiovascular risk factors are present. Symptoms of recurrent Achilles tendonitis or arthritic complaints may be present.</p>
        <p>
<bold>Family History</bold>
</p>
        <p>Careful family history is essential for the assessment and diagnosis of familial hypercholesterolemia. Family history of premature coronary artery disease or high cholesterol in first-degree relatives (younger than 60 years in women and 55 years in men among first-degree relatives) are red flags.<xref ref-type="bibr" rid="article-23166.r22">[22]</xref>&#x000a0;It should also raise the suspicion for familial hypercholesterolemia&#x000a0;with young patients&#x000a0;showing early coronary events in second-degree relatives.<xref ref-type="bibr" rid="article-23166.r16">[16]</xref></p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Usually, abnormal physical examinations are related to depositions of cholesterol in the eye or skin. It can happen at an early age with homozygous familial hypercholesterolemia.<xref ref-type="bibr" rid="article-23166.r22">[22]</xref>&#x000a0;Tendon xanthomas are pathognomonic for familial hypercholesterolemia and manifest as thickening of the tendons due to cholesterol deposited within macrophages in connective tissue (lipid-laden histiocytes). The Achilles tendon and finger extensor tendons are the most common sites, however patellar and triceps tendons are not unusual. Tendon xanthomas occur in less than half of patients with FH.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref>&#x000a0;Corneal arcus senilis are depositions of cholesterol around the corneal rim. It is more specific in a patient younger than 45 years of age. Cholesterol deposition can also manifest as yellow-orange tuberous xanthomas (on hands, elbows, or knees) or xanthelasma (in the eyelids), which are more specific for FH in patients aged 20 to 25 years.<xref ref-type="bibr" rid="article-23166.r23">[23]</xref></p>
      </sec>
      <sec id="article-23166.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Screening for Familial Hypercholesterolemia</bold>
</p>
        <p>Screening for familial hypercholesterolemia should occur in people age 2 years and older if the patient has a family history of hypercholesterolemia or premature CHD.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref>&#x000a0;Universal screening, including measurement of a non-fasting non-high-density lipoprotein (HDL) cholesterol or fasting lipid profile, is recommended to diagnose children with familial hypercholesterolemia at ages 9 to 11 years.<xref ref-type="bibr" rid="article-23166.r24">[24]</xref>&#x000a0;Children with a non-fasting non-HDL cholesterol result 145 mg/dL and higher need to be evaluated by fasting lipid profile.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
        <p>
<bold>Suspicious for&#x000a0;Familial Hypercholesterolemia</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>In people 20 years old or younger: if untreated fasting serum LDL cholesterol levels are 160 mg/dL and higher or non-HDL cholesterol levels are 190 mg/dL and higher</p>
          </list-item>
          <list-item>
            <p>In adults older than 20 years: if fasting LDL cholesterol levels are 190 mg/dL and higher or non-HDL cholesterol is 220 mg/dL and higher.<xref ref-type="bibr" rid="article-23166.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>FH in the family member or total cholesterol greater than 240 mg/dL in either parent.<xref ref-type="bibr" rid="article-23166.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Tendon xanthomas at any age, corneal arcus senilis in a patient younger than 45 years of age, and yellow-orange xanthelasma tuberous or xanthomas in a patient aged 20 to 25 years.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Genetic Tests or Clinical Criteria/Diagnostic Criteria for Heterozygous FH (HeFH) and Homozygous FH(HoFH)</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Heterozygous FH (HeFH): The two most commonly used criteria for evaluating and diagnosing FH are the Dutch lipid clinic criteria and the Simon Broome criteria.<xref ref-type="bibr" rid="article-23166.r26">[26]</xref><xref ref-type="bibr" rid="article-23166.r27">[27]</xref>&#x000a0;Both incorporate LDL levels, presence of xanthomas, the presence of a genetic mutation or family history of FH, premature cardiovascular events, tendinous xanthomas, or corneal arcus senilis, and elevated LDL levels in young ages. The Dutch lipid clinic criteria categorize patients into definite, probable, possible, or unlikely FH, while Simon Broome classifies patients as definite or possible. Having only an LDL level of 330 mg/dl or more, or a mutation in the LDL receptor, ApoB-100, or the PCSK9 gene will earn a diagnosis of probable FH, based on the Dutch lipid clinic criteria. If a patient has any of the additional factors of the Dutch lipid clinic, on top of the gene mutation or the LDL level, as mentioned above, the diagnosis becomes definite FH. Based on the Simon Broom criteria, a diagnosis of definite FH requires an LDL level of at least 155 mg/dl and a gene mutation or tendinous xanthomas in the patient or first- or second-degree relatives. Generally, genetic screening for FH is not required for diagnosis, but it is helpful when the diagnosis is uncertain. However, approximately 20% of patients with FH are diagnosed with clinical criteria, and genetic tests are negative for mutations.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Homozygous FH (HoFH): Clinically, HoFH is diagnosed based on untreated LDL-C plasma level greater than 500 mg/dL (more than 13 mmol/L) or treated LDL-C plasma concentration equal to or greater than 300 mg/dL (more than 8 mmol/L), and the&#x000a0;presence of&#x000a0;tendon xanthoma or cutaneous manifestation before the age of 10 years or both parents has consistent criteria for HeFH based on the untreated elevation of LDL-C levels.<xref ref-type="bibr" rid="article-23166.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cascade Screening</bold>
</p>
        <p>Cascade screening is defined as evaluation and screening that involves family members of the patient with FH.<xref ref-type="bibr" rid="article-23166.r28">[28]</xref>&#x000a0;Cascade screening include lipid profile test in all first-degree family members of diagnosed patients with FH. The&#x000a0;odds for detecting familial hypercholesterolemia in first, second, and third-degree relatives is 50%, 25%, and 12.5%, respectively. If genetic mutations are found in a patient, then the patient's family member also needs to receive genetic screening.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
        <p>
<bold>Radiology</bold>
</p>
        <p>Doppler echocardiographic evaluation of the heart and aorta is recommended annually in patients with homozygous FH.&#x000a0;Radiographic imaging of the Achilles tendon helps accurately measure Achilles tendon xanthomas.</p>
        <p>
<bold>Biopsy</bold>
</p>
        <p>If a skin lesion or the diagnosis of heterozygous FH is unclear, a biopsy of the skin lesion can be performed. Both xanthelasmas and the xanthomas of FH contain accumulations of cholesterol.</p>
      </sec>
      <sec id="article-23166.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Approach to Therapy</bold>
</p>
        <p>All patients with familial hypercholesterolemia and their families should receive education&#x000a0;regarding lifestyle management. This&#x000a0;includes&#x000a0;a healthy diet, quitting smoking, and physical therapy/activity. Dietitians or nutritionists should advise patients and family members to reduce the amount of food with high cholesterol and encourage them to lose weight.<xref ref-type="bibr" rid="article-23166.r29">[29]</xref> A holistic approach should be sought in the treatment of FH. Besides lowering LDL levels, controlling the patient&#x02019;s lifestyle risk, and other modifiable risk factors of coronary heart disease is essential in reducing CV morbidity and mortality in these patients. Setting a suitable target LDL level is difficult, as patients with FH present with varying degrees of elevated LDL levels. Most guidelines recommend a reduction of 50% or more&#x000a0;from the initial untreated LDL level in patients with FH.<xref ref-type="bibr" rid="article-23166.r30">[30]</xref><xref ref-type="bibr" rid="article-23166.r31">[31]</xref>&#x000a0;Some guidelines consider patients with prior coronary heart disease or concomitant diabetes are considered high risk, and&#x000a0;the recommendation is to have an LDL level below 70 mg/dL, while patients without prior coronary heart disease or diabetes are considered the low-moderate risk and have recommended target LDL level below 100 mg/dL. LDL levels should be checked every 2 to 3 months while on treatment to adjust drug therapies accordingly.<xref ref-type="bibr" rid="article-23166.r32">[32]</xref></p>
        <p>
<bold>Drug Therapies</bold>
</p>
        <p>Statins are the standard therapy for familial hypercholesterolemia. All guidelines recommend statins as first-line drugs for patients with FH, with a goal of reaching maximally tolerated doses.<xref ref-type="bibr" rid="article-23166.r33">[33]</xref>&#x000a0;The effect of statins has been well studied, and most randomized clinical trials observed a reduction of around 50 percent of the initial untreated LDL levels, as well as a reduction in cardiovascular events.<xref ref-type="bibr" rid="article-23166.r34">[34]</xref><xref ref-type="bibr" rid="article-23166.r35">[35]</xref><xref ref-type="bibr" rid="article-23166.r36">[36]</xref>&#x000a0;Unfortunately, a large number of patients with FH, even on maximally-tolerated statins alone, either do not show this level of reduction in LDL levels, or they do not reach their goal LDL levels, even with a 50 percent reduction, because their initial LDL levels are so high.<xref ref-type="bibr" rid="article-23166.r35">[35]</xref>&#x000a0;Second-line therapies include ezetimibe and PCSK9 inhibitors. Ezetimibe has been showing to add an extra 10 to 30 percent reduction in LDL levels for patients on maximally tolerated statins.<xref ref-type="bibr" rid="article-23166.r37">[37]</xref><xref ref-type="bibr" rid="article-23166.r38">[38]</xref>&#x000a0;Currently, ezetimibe is the drug of choice as the second line in most guidelines.<xref ref-type="bibr" rid="article-23166.r39">[39]</xref>&#x000a0;PCSK9 inhibitors have shown a great reduction in LDL levels and cardiovascular outcomes in different randomized clinical trials.<xref ref-type="bibr" rid="article-23166.r22">[22]</xref><xref ref-type="bibr" rid="article-23166.r40">[40]</xref>&#x000a0;In those trials, PCKS9 inhibitors lowered LDL levels by 50 to 60 percent. While exhibiting higher efficacy than ezetimibe, the use of PCSK9 inhibitors is limited by their high cost and the reluctance of insurance companies to approve their use.<xref ref-type="bibr" rid="article-23166.r41">[41]</xref>&#x000a0;Hence, PCSK9 inhibitors can be used as second or third-line drugs for patients with familial hypercholesterolemia. Fourth line therapies include mipomersen (mRNA inhibition of apolipoprotein B), lomitapide (microsomal triglyceride transfer protein inhibition), niacin, lipoprotein apheresis, ileal bypass surgery, and liver transplantation.<xref ref-type="bibr" rid="article-23166.r42">[42]</xref><xref ref-type="bibr" rid="article-23166.r43">[43]</xref><xref ref-type="bibr" rid="article-23166.r44">[44]</xref><xref ref-type="bibr" rid="article-23166.r45">[45]</xref>&#x000a0;These are usually reserved if the LDL does not reach the target level using statins, ezetimibe, and PCSK9 inhibitors.<xref ref-type="bibr" rid="article-23166.r44">[44]</xref></p>
        <p>
<bold>Treatment Guidelines for Homozygous FH</bold>
</p>
        <p>European Atherosclerosis Society (EAS) guidelines for the screening and treatment of homozygous FH are summarized as follows:<xref ref-type="bibr" rid="article-23166.r46">[46]</xref><xref ref-type="bibr" rid="article-23166.r47">[47]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of homozygous FH involves a combination of lifestyle changes, statin therapy (first approach), and lipoprotein apheresis for severe cases</p>
          </list-item>
          <list-item>
            <p>LDL apheresis should begin as early as age 5 years</p>
          </list-item>
          <list-item>
            <p>For homozygous FH patients, the LDL cholesterol targets are less than 100 mg/dL for adults, less than 70 mg/dL for adults with clinical cardiovascular disease (CVD), and less than 135 mg/dL for children</p>
          </list-item>
          <list-item>
            <p>Other novel agents for LDL cholesterol lowering (eg, lomitapide with or without apheresis) can be considered as adjunctive treatments for patients who do not achieve the recommended LDL cholesterol targets and remain at high cardiovascular risk.</p>
          </list-item>
        </list>
        <p>
<bold>Treatment Guidelines for Heterozygous FH</bold>
</p>
        <p>In patients with heterozygous FH, lifestyle modification is unlikely to result in acceptable LDLc levels; therefore, cholesterol-lowering medication is necessary. EAS consensus statement for screening and treatment of heterozygous FH includes the following recommendations:<xref ref-type="bibr" rid="article-23166.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>An LDL target of less than 135 mg/dL for children with FH</p>
          </list-item>
          <list-item>
            <p>An LDL target of less than 100 mg/dL for adults with FH</p>
          </list-item>
          <list-item>
            <p>An LDL target of less than 70 mg/dL for adults with known CHD or diabetes</p>
          </list-item>
          <list-item>
            <p>Lifestyle modifications include a diet that severely limits saturated fats,&#x000a0;<italic toggle="yes">trans</italic>&#x000a0;fats, and cholesterol</p>
          </list-item>
          <list-item>
            <p>Desirable weight should be attained</p>
          </list-item>
          <list-item>
            <p>Significant weight loss should improve all lipid parameters (LDLc, HDLc, triglycerides)</p>
          </list-item>
          <list-item>
            <p>Aerobic and toning exercises improve blood lipid levels if performed for longer than 30 minutes, 4 or more days per week</p>
          </list-item>
        </list>
        <p>
<bold>Familial Hypercholesterolemia and Pregnancy</bold>
</p>
        <p>Women with familial hypercholesterolemia planning to conceive should discontinue all lipid-lowering agents, including statins, ezetimibe, and PCSK9 inhibitors. Cardiovascular risk assessment is recommended before conception. Lipoprotein apheresis may be used if necessary.<xref ref-type="bibr" rid="article-23166.r48">[48]</xref></p>
        <p>
<bold>Surgical Care</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver transplantation for homozygous FH because a new liver provides functional LDL receptors and causes dramatic decreases in LDLc levels</p>
          </list-item>
          <list-item>
            <p>Portacaval anastomosis for homozygous FHT</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23166.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses of familial hypercholesterolemia include but are not limited to the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sitosterolemia - an autosomal recessive disorder leading to&#x000a0;hyperabsorption of plant sterols from the intestine and elevation of plant sterol concentrations in tissues<xref ref-type="bibr" rid="article-23166.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Cerebrotendinous xanthomatosis - an autosomal recessive disorder caused by a defective block in bile acid synthesis enzyme leading to&#x000a0;the deposition of cholestanol and cholesterol ocular, neurological, vascular, and musculoskeletal<xref ref-type="bibr" rid="article-23166.r50">[50]</xref></p>
          </list-item>
          <list-item>
            <p>Polygenic hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Familial combined hyperlipidemia</p>
          </list-item>
          <list-item>
            <p>Hyperapobetalipoproteinemia</p>
          </list-item>
          <list-item>
            <p>Familial dysbetalipoproteinemia (type 3 hyperlipoproteinemia)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23166.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The risk of coronary heart disease before the use of statin in patients with heterozygous familial hypercholesterolemia was very high.<xref ref-type="bibr" rid="article-23166.r51">[51]</xref>&#x000a0;However, the risk of death in patients with heterozygous FH after acute coronary syndrome within the first year is almost more than two times higher than matched individuals without familial hypercholesterolemia despite high-intensity statins therapy.<xref ref-type="bibr" rid="article-23166.r52">[52]</xref>&#x000a0;The risk of death or coronary artery disease in relatives of patients with FH was 52% and 32% in males and females, respectively.<xref ref-type="bibr" rid="article-23166.r53">[53]</xref>&#x000a0;Patients with homozygous FH have a poor prognosis. They usually die before the third decade of life from cardiovascular events.<xref ref-type="bibr" rid="article-23166.r22">[22]</xref></p>
      </sec>
      <sec id="article-23166.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Familial hypercholesterolemia can lead to serious complications. These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stable coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Fatal and non-fatal myocardial infarctions</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Cerebrovascular accidents</p>
          </list-item>
          <list-item>
            <p>Aortic stenosis</p>
          </list-item>
          <list-item>
            <p>Peripheral arterial disease</p>
          </list-item>
          <list-item>
            <p>Cardiovascular death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23166.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultation with certified dietitians/nutritionists should support implementing&#x000a0;a healthy diet&#x000a0;for the patient and their whole family. Refer to the lipid specialist or familial hypercholesterolemia clinic recommendations whenever, despite maximally tolerated statins, LDL cholesterol is still above goal.<xref ref-type="bibr" rid="article-23166.r16">[16]</xref>&#x000a0;Management of patients with familial hypercholesterolemia requires an interprofessional approach, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary care providers</p>
          </list-item>
          <list-item>
            <p>Cardiologists</p>
          </list-item>
          <list-item>
            <p>Endocrinologists</p>
          </list-item>
          <list-item>
            <p>Lipid specialists</p>
          </list-item>
          <list-item>
            <p>Dietitians</p>
          </list-item>
          <list-item>
            <p>Pharmacists</p>
          </list-item>
          <list-item>
            <p>Nurses</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23166.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with familial hypercholesterolemia should be educated about a healthy lifestyle, quitting smoking, and taking measures to avoid being overweight. A healthy lifestyle should include reducing&#x000a0;food and beverages with high cholesterol, trans fat content, and saturated fat. Also, patients should consider foods resulting in a decrease in cholesterol, such as plant stanols and sterols.<xref ref-type="bibr" rid="article-23166.r16">[16]</xref></p>
        <p>Patients with familial hypercholesterolemia should also&#x000a0;receive education regarding their risk of CV disease. Patients should&#x000a0;learn about controlling all modifiable risk factors&#x000a0;for CV disease and treatment strategies&#x000a0;for familial hypercholesterolemia once a diagnosis is made. All first-degree relatives of patients with FH should be counseled about the importance of screening.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
      </sec>
      <sec id="article-23166.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Familial hypercholesterolemia is a common cause of premature cardiovascular events in children and adults.</p>
          </list-item>
          <list-item>
            <p>Various diagnostic criteria of familial hypercholesterolemia are available online and can help direct further workup.</p>
          </list-item>
          <list-item>
            <p>Heterozygous FH is underrecognized and commonly treated sub-optimally.</p>
          </list-item>
          <list-item>
            <p>Screening of first-degree relatives of patients with FH is essential in the primary prevention of CV events.</p>
          </list-item>
          <list-item>
            <p>Referral to a lipid specialist can help optimize the control of LDL hypercholesterolemia in patients with FH.<xref ref-type="bibr" rid="article-23166.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23166.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Optimal screening and diagnosis of familial hypercholesterolemia are paramount in the prevention of premature cardiovascular events. Management of patients with familial hypercholesterolemia requires an interprofessional approach, including primary care providers, cardiologists, endocrinologists, lipid specialists, dietitians, pharmacists, and nursing care, to improve outcomes. An extensive discussion of treatment strategies should be done at diagnosis. A close follow-up to observe the response to treatment and development of side effects from lipid-lowering agents is essential in optimizing care.<xref ref-type="bibr" rid="article-23166.r16">[16]</xref>&#x000a0;[Level 3]</p>
      </sec>
      <sec id="article-23166.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23166&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23166">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/familial-hypercholesterolemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23166">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23166/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23166">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23166.s17">
        <title>References</title>
        <ref id="article-23166.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The LDL receptor locus and the genetics of familial hypercholesterolemia.</article-title>
            <source>Annu Rev Genet</source>
            <year>1979</year>
            <volume>13</volume>
            <fpage>259</fpage>
            <page-range>259-89</page-range>
            <pub-id pub-id-type="pmid">231932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roederer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Minnich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davignon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations.</article-title>
            <source>Atherosclerosis</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-24</page-range>
            <pub-id pub-id-type="pmid">10580177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Civeira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jarauta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cenarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Ot&#x000ed;n</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tejedor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zamb&#x000f3;n</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pocov&#x000ed;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2008</year>
            <month>Nov</month>
            <day>04</day>
            <volume>52</volume>
            <issue>19</issue>
            <fpage>1546</fpage>
            <page-range>1546-53</page-range>
            <pub-id pub-id-type="pmid">19007590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia: a challenge of diagnosis and therapy.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">16444917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khera</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Peloso</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Bartz</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Emdin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bick</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Duga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bis</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>van Duijn</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cupples</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Psaty</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Danesh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schunkert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Farrall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lander</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boerwinkle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ardissino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saleheen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kathiresan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jun</month>
            <day>07</day>
            <volume>67</volume>
            <issue>22</issue>
            <fpage>2578</fpage>
            <page-range>2578-89</page-range>
            <pub-id pub-id-type="pmid">27050191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sjouke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kusters</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kindt</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Besseling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Defesche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sijbrands</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Roeters van Lennep</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Wiegman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fouchier</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Mar</month>
            <day>01</day>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>560</fpage>
            <page-range>560-5</page-range>
            <pub-id pub-id-type="pmid">24585268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khachadurian</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Uthman</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients.</article-title>
            <source>Nutr Metab</source>
            <year>1973</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <page-range>132-40</page-range>
            <pub-id pub-id-type="pmid">4351242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>PCSK9: a convertase that coordinates LDL catabolism.</article-title>
            <source>J Lipid Res</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>50 Suppl</volume>
            <issue>Suppl</issue>
            <fpage>S172</fpage>
            <page-range>S172-7</page-range>
            <pub-id pub-id-type="pmid">19020338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fouchier</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Dallinga-Thie</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Meijers</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zelcer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Defesche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.</article-title>
            <source>Circ Res</source>
            <year>2014</year>
            <month>Aug</month>
            <day>29</day>
            <volume>115</volume>
            <issue>6</issue>
            <fpage>552</fpage>
            <page-range>552-5</page-range>
            <pub-id pub-id-type="pmid">25035151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Rodday</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Sheldrick</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES).</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>133</volume>
            <issue>11</issue>
            <fpage>1067</fpage>
            <page-range>1067-72</page-range>
            <pub-id pub-id-type="pmid">26976914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Tybj&#x000e6;rg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>May</month>
            <day>01</day>
            <volume>37</volume>
            <issue>17</issue>
            <fpage>1384</fpage>
            <page-range>1384-94</page-range>
            <pub-id pub-id-type="pmid">26908947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Couture</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morissette</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaudet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vohl</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gagn&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergeron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Despr&#x000e9;s</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations.</article-title>
            <source>Atherosclerosis</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>145</fpage>
            <page-range>145-51</page-range>
            <pub-id pub-id-type="pmid">10208489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steyn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Kotze</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Steyn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swanepoel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fourie</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Coetzee</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Van der Westhuyzen</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations.</article-title>
            <source>Hum Genet</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>479</fpage>
            <page-range>479-84</page-range>
            <pub-id pub-id-type="pmid">8792826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>National Lipid Association Expert Panel on Familial Hypercholesterolemia</collab>
            </person-group>
            <article-title>Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.</article-title>
            <source>J Clin Lipidol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3 Suppl</issue>
            <fpage>S9</fpage>
            <page-range>S9-17</page-range>
            <pub-id pub-id-type="pmid">21600530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arias-Moreno</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Velazquez-Campoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pocov&#x000ed;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sancho</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of low density lipoprotein (LDL) release in the endosome: implications of the stability and Ca2+ affinity of the fifth binding module of the LDL receptor.</article-title>
            <source>J Biol Chem</source>
            <year>2008</year>
            <month>Aug</month>
            <day>15</day>
            <volume>283</volume>
            <issue>33</issue>
            <fpage>22670</fpage>
            <page-range>22670-9</page-range>
            <pub-id pub-id-type="pmid">18574243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Masana</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Defesche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wiegman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Parhofer</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Kovanen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Averna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bruckert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kuivenhoven</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pajukanta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tybj&#x000e6;rg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <collab>European Atherosclerosis Society Consensus Panel</collab>
            </person-group>
            <article-title>Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.</article-title>
            <source>Eur Heart J</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>45</issue>
            <fpage>3478</fpage>
            <page-range>3478-90a</page-range>
            <pub-id pub-id-type="pmid">23956253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steinberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parthasarathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carew</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Witztum</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.</article-title>
            <source>N Engl J Med</source>
            <year>1989</year>
            <month>Apr</month>
            <day>06</day>
            <volume>320</volume>
            <issue>14</issue>
            <fpage>915</fpage>
            <page-range>915-24</page-range>
            <pub-id pub-id-type="pmid">2648148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hobbs</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein.</article-title>
            <source>Annu Rev Genet</source>
            <year>1990</year>
            <volume>24</volume>
            <fpage>133</fpage>
            <page-range>133-70</page-range>
            <pub-id pub-id-type="pmid">2088165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abifadel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rab&#x000e8;s</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Genetic heterogeneity of autosomal dominant hypercholesterolemia.</article-title>
            <source>Clin Genet</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">18028451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tybjaerg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Houlston</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Talmud</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dunning</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Seed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamsten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Myant</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases.</article-title>
            <source>Atherosclerosis</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-42</page-range>
            <pub-id pub-id-type="pmid">2310429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Molecular biology of PCSK9: its role in LDL metabolism.</article-title>
            <source>Trends Biochem Sci</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-7</page-range>
            <pub-id pub-id-type="pmid">17215125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuchel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bruckert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kuivenhoven</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Steinhagen-Thiessen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tybj&#x000e6;rg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Averna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Defesche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kovanen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Masana</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pajukanta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parhofer</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Wiegman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia</collab>
            </person-group>
            <article-title>Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>Aug</month>
            <day>21</day>
            <volume>35</volume>
            <issue>32</issue>
            <fpage>2146</fpage>
            <page-range>2146-57</page-range>
            <pub-id pub-id-type="pmid">25053660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.</article-title>
            <source>CMAJ</source>
            <year>2006</year>
            <month>Apr</month>
            <day>11</day>
            <volume>174</volume>
            <issue>8</issue>
            <fpage>1124</fpage>
            <page-range>1124-9</page-range>
            <pub-id pub-id-type="pmid">16606962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wald</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bestwick</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2007</year>
            <month>Sep</month>
            <day>22</day>
            <volume>335</volume>
            <issue>7620</issue>
            <fpage>599</fpage>
            <pub-id pub-id-type="pmid">17855284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Leppert</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.</article-title>
            <source>Am J Cardiol</source>
            <year>1993</year>
            <month>Jul</month>
            <day>15</day>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-6</page-range>
            <pub-id pub-id-type="pmid">8328379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Defesche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lansberg</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Umans-Eckenhausen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Advanced method for the identification of patients with inherited hypercholesterolemia.</article-title>
            <source>Semin Vasc Med</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-65</page-range>
            <pub-id pub-id-type="pmid">15199434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wierzbicki</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>R</given-names>
              </name>
              <collab>Guideline Development Group</collab>
            </person-group>
            <article-title>Familial hypercholesterolaemia: summary of NICE guidance.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Aug</month>
            <day>27</day>
            <volume>337</volume>
            <fpage>a1095</fpage>
            <pub-id pub-id-type="pmid">18753174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaseghi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haghjooy-Javanmard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sabri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadeghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khosravi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zarfeshani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarrafzadegan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>CASCADE screening and registry of familial hypercholesterolemia in Iran: Rationale and design.</article-title>
            <source>ARYA Atheroscler</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>53</fpage>
            <page-range>53-58</page-range>
            <pub-id pub-id-type="pmid">31440286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broekhuizen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jelsma</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>van Poppel</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Koppes</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Brug</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Mechelen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with familial hypercholesterolemia?</article-title>
            <source>BMC Public Health</source>
            <year>2012</year>
            <month>May</month>
            <day>14</day>
            <volume>12</volume>
            <fpage>348</fpage>
            <pub-id pub-id-type="pmid">22583789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee</collab>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>05</day>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-125</page-range>
            <pub-id pub-id-type="pmid">27046161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cromwell</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ziajka</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.</article-title>
            <source>J Clin Lipidol</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-140</page-range>
            <pub-id pub-id-type="pmid">21600517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>10. Cardiovascular Disease and Risk Management: <italic>Standards of Medical Care in Diabetes-2019</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>Suppl 1</issue>
            <fpage>S103</fpage>
            <page-range>S103-S123</page-range>
            <pub-id pub-id-type="pmid">30559236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bairey Merz</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Eckel</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shero</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PW</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Jul</month>
            <day>01</day>
            <volume>63</volume>
            <issue>25 Pt B</issue>
            <fpage>2889</fpage>
            <page-range>2889-934</page-range>
            <pub-id pub-id-type="pmid">24239923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kafonek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laurora</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).</article-title>
            <source>Am J Cardiol</source>
            <year>1998</year>
            <month>Mar</month>
            <day>01</day>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>582</fpage>
            <page-range>582-7</page-range>
            <pub-id pub-id-type="pmid">9514454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smilde</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>van Wissen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wollersheim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trip</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Feb</month>
            <day>24</day>
            <volume>357</volume>
            <issue>9256</issue>
            <fpage>577</fpage>
            <page-range>577-81</page-range>
            <pub-id pub-id-type="pmid">11558482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>deGoma</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Kindt</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shrader</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Pokharel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hemphill</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hudgins</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wilemon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Linton</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Duell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.</article-title>
            <source>Circ Cardiovasc Genet</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>240</fpage>
            <page-range>240-9</page-range>
            <pub-id pub-id-type="pmid">27013694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Blazing</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lokhnygina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Reist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bohula</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Isaza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dellborg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Tershakovec</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>02</day>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>353</fpage>
            <page-range>353-361</page-range>
            <pub-id pub-id-type="pmid">26821621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Akdim</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Zwinderman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bots</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Visseren</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Sijbrands</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Trip</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gaudet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Duivenvoorden</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Veltri</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>E</given-names>
              </name>
              <collab>ENHANCE Investigators</collab>
            </person-group>
            <article-title>Simvastatin with or without ezetimibe in familial hypercholesterolemia.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Apr</month>
            <day>03</day>
            <volume>358</volume>
            <issue>14</issue>
            <fpage>1431</fpage>
            <page-range>1431-43</page-range>
            <pub-id pub-id-type="pmid">18376000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>25</day>
            <volume>73</volume>
            <issue>24</issue>
            <fpage>e285</fpage>
            <page-range>e285-e350</page-range>
            <pub-id pub-id-type="pmid">30423393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Keech</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Honarpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kuder</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <collab>FOURIER Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>04</day>
            <volume>376</volume>
            <issue>18</issue>
            <fpage>1713</fpage>
            <page-range>1713-1722</page-range>
            <pub-id pub-id-type="pmid">28304224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arrieta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Nasir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.</article-title>
            <source>JAMA Cardiol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>1369</fpage>
            <page-range>1369-1374</page-range>
            <pub-id pub-id-type="pmid">29049467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kirwan</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Witztum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tsimikas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJP</given-names>
              </name>
            </person-group>
            <article-title>Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.</article-title>
            <source>J Clin Lipidol</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>1011</fpage>
            <page-range>1011-1021</page-range>
            <pub-id pub-id-type="pmid">27578134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuchel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meagher</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>du Toit Theron</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Averna</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sirtori</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Gaudet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stefanutti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vigna</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Du Plessis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Propert</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Sasiela</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Bloedon</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>Phase 3 HoFH Lomitapide Study investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Jan</month>
            <day>05</day>
            <volume>381</volume>
            <issue>9860</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">23122768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchwald</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Partial ileal bypass in the therapy of familial hypercholesterolemia. The POSCH Group.</article-title>
            <source>Beitr Infusionsther</source>
            <year>1988</year>
            <volume>23</volume>
            <fpage>47</fpage>
            <page-range>47-60</page-range>
            <pub-id pub-id-type="pmid">2484782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuzaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiramori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitabatake</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hishida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakuma</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fukami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamagishi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2002</year>
            <month>Jul</month>
            <day>17</day>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <page-range>220-7</page-range>
            <pub-id pub-id-type="pmid">12106923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baigent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Koskinas</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Casula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badimon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ference</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mihaylova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Riccardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tokgozoglu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.</article-title>
            <source>Eur Heart J</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-188</page-range>
            <pub-id pub-id-type="pmid">31504418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia treatments: Guidelines and new therapies.</article-title>
            <source>Atherosclerosis</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>277</volume>
            <fpage>483</fpage>
            <page-range>483-492</page-range>
            <pub-id pub-id-type="pmid">30270089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Champagne</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Defesche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McCrindle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Lopes-Virella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Wierzbicki</surname>
                <given-names>AS</given-names>
              </name>
              <collab>American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health</collab>
            </person-group>
            <article-title>The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>132</volume>
            <issue>22</issue>
            <fpage>2167</fpage>
            <page-range>2167-92</page-range>
            <pub-id pub-id-type="pmid">26510694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veit</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Allegri Machado</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Speer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>H&#x000e4;berle</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sitosterolemia-10 years observation in two sisters.</article-title>
            <source>JIMD Rep</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-10</page-range>
            <pub-id pub-id-type="pmid">31392106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parry</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gojwari</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Cerebrotendinous xanthomatosis - A case report.</article-title>
            <source>Indian J Radiol Imaging</source>
            <year>2019</year>
            <season>Jul-Sep</season>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-334</page-range>
            <pub-id pub-id-type="pmid">31741606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Austin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hutter</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zimmern</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia and coronary heart disease: a HuGE association review.</article-title>
            <source>Am J Epidemiol</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>160</volume>
            <issue>5</issue>
            <fpage>421</fpage>
            <page-range>421-9</page-range>
            <pub-id pub-id-type="pmid">15321838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nanchen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gencer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Auer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aghlmandi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klingenberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>R&#x000e4;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carballo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carballo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matter</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>L&#x000fc;scher</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rodondi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Sep</month>
            <day>06</day>
            <volume>134</volume>
            <issue>10</issue>
            <fpage>698</fpage>
            <page-range>698-709</page-range>
            <pub-id pub-id-type="pmid">27462068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23166.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Fredrickson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Verter</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.</article-title>
            <source>Circulation</source>
            <year>1974</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>476</fpage>
            <page-range>476-88</page-range>
            <pub-id pub-id-type="pmid">4813182</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
